Skin Cream RLS-1496 Shows Potential in Preliminary Trials
The treatment aims to reduce skin lesions and age markers by clearing away damaged cells over several weeks.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Would you try an experimental skin treatment before it receives full clinical peer review?
Rubedo Life Sciences has shared preliminary findings from research on RLS-1496, an experimental cream designed to treat skin aging and lesions. The results suggest the treatment, which is still in the research stage, may reduce epigenetic skin age and lesion counts.
Why it matters
By targeting senescent cells—cells that have stopped dividing but continue to cause inflammation—this approach moves away from traditional cosmetic treatments toward biological management of skin tissue aging.
The study measured a 10% increase in collagen and a 2.1-year average decrease in epigenetic skin age over four weeks of treatment. These figures, derived from 11 paired samples, compare results against pre-treatment baselines in patients with atopic dermatitis.
The players
Rubedo Life Sciences
A Mountain View-based biotechnology company focused on developing therapies that target cellular senescence to address age-related diseases.
The details
The treatment works by targeting GPX4, a protein essential for the survival of senescent cells, to clear away these damaged, aging components from the skin. In the actinic keratosis study, researchers tracked the efficacy of this mechanism over 28 days by comparing treated forearms to untreated control sites on 22 patients.
Timeline
October 2026: Rubedo Life Sciences released preliminary data on RLS-1496.
28 days: Duration of treatment in the actinic keratosis study.
Four weeks: Duration of treatment in the skin-aging study.
3 to 4 years: Estimated timeline for potential FDA approval.
The Tech Race
This development follows the trajectory of emerging senolytic research, which aims to eliminate damaged cells rather than manage symptoms. It remains an early-stage effort within the broader race to develop treatments that fundamentally alter cellular aging.
The treatment is currently in the research phase and is not available for clinical or cosmetic use. Patients should expect further testing, with potential FDA approval estimated to be three to four years away.
The takeaway
The effectiveness of this protein-targeting approach remains to be confirmed through full, peer-reviewed clinical data. Readers should watch for the results of the next planned trial, which will extend treatment duration for several months.
Further reading
For more on the current landscape of cellular therapies, see the Biotech section.
Live Poll
Would you try an experimental skin treatment before it receives full clinical peer review?
